Northpond Ventures

Selected news for the capital firm - Northpond Ventures, collected since 4/2019. Recent stories appear in FierceHealthcare and bollyinside.com. This capital firm shares healthcare news with DNAnexus, Regeneron, Regeneron Pharmaceuticals and many others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
4/23/2021 Current Health banks $43M to expand remote care management platform FierceHealthcare ... company, which launched in Scotland in 2015 and now has offices in Boston, pulled in $43 million in series B financing from top healthcare and pharmaceutical venture capital investors.The round was led by Northpond Ventures with additional financing from LRVHealth, OSF HealthCare, Section 32, Elements Health Ventures and existing investors.Andrea Jackson, director at Northpond Ventures , and Tripp Peake, general partner at LRVHealth, will join Current Health’s board ...
4/23/2021 Today's Healthcare Raises $ 43 Million – We’re the Glue That Enables Safer Home Health Care bollyinside.com Buzz Staff 2021-04-23The Series B was led by Northpond Ventures , with additional financing from LRVHealth, OSF HealthCare, Section 32, Elements Health Ventures and existing investors. “These represent some of the most sophisticated and thoughtful professional investments within health care and life sciences,” Chris McCann, CEO and co-founder at Current Health, told Home Health Care News. “The expertise they bring in building companies successfully in that space is ...
4/23/2021 Current Health draws $43M in series B funding to grow telehealth platform FierceBiotech Still riding the wave of its massive growth in 2020, Current Health has closed an overstuffed funding round in support of its remote care management platform.The $43 million series B was led by Northpond Ventures . Also participating in the round were LRVHealth, OSF HealthCare, Section 32, Elements Health Ventures and several of the company’s existing investors.Alongside the influx of new funding, Current Health will also expand its ...
4/22/2021 Current Health Closes Oversubscribed $43M Series B Financing Round to Scale Remote Care Management Platform | Financial Buzz financialbuzz.com Current Health – the leading enterprise remote care management platform – today announced it has raised $43M in Series B financing. The round was led by Northpond Ventures , with additional financing from LRVHealth, OSF HealthCare, Section 32, Elements Health Ventures, and existing investors. Andrea Jackson, Director at Northpond Ventures , and Tripp Peake, General Partner at LRVHealth, will join Current Health’s Board of Directors.The Series B financing, which comes ...
4/22/2021 Current Health closes $43M Series B for company growth, Medchart raises $17M for product innovation and more digital health fundings MobiHealthNews ... round and Oath Care lands $2M ahead of its launch later this year. SharePhoto by IronHeart/Getty ImagesRemote care management platform Current Health has closed a $43 million Series B financing round. Northpond Ventures led the round, along with LRVHealth, OSF HealthCare, Section 32, Elements Health Ventures and existing investors.In addition to the financing, Current Health is adding Andrea Jackson, Director at Northpond Ventures , and Tripp Peake ...
4/22/2021 Current Health Raises $43M: We’re the Glue Enabling Safer Health Care at Home Home Health Care News ... in real time, allowing clinicians to provide enhanced virtual care for patients at home and in facilities. Its tacking includes respiratory rate, oxygen saturation, skin temperature and more.The Series B was led by Northpond Ventures , with additional financing from LRVHealth, OSF HealthCare, Section 32, Elements Health Ventures and existing investors. Advertisement“These represent some of the most sophisticated and thoughtful professional investments within health care and life sciences,” ...
4/22/2021 Current Health's Rapid Growth Helps it Land $43M Financing MDDI ... Äôs recent financing is an example of the increased amount of attention being paid to the space. The company has raised $43 million in a series B financing round.The round was led by Northpond Ventures , with additional financing from LRVHealth, OSF HealthCare, Section 32, Elements Health Ventures, and existing investors.Current Health has developed an artificial intelligence-powered remote monitoring solution. The platform was cleared by FDA in April ...
4/22/2021 Current Health Closes Oversubscribed $43M Series B Financing Round to Scale Remote Care Management Platform | Business Wire Business Wire BOSTON--( BUSINESS WIRE )-- Current Health – the leading enterprise remote care management platform – today announced it has raised $43M in Series B financing. The round was led by Northpond Ventures , with additional financing from LRVHealth, OSF HealthCare, Section 32, Elements Health Ventures, and existing investors. Andrea Jackson, Director at Northpond Ventures , and Tripp Peake, General Partner at LRVHealth, will join Current Health’s Board of Directors.The Series B ...
4/20/2021 VieCure Announces $25 Million Series A Investment Led by Northpond Ventures to Improve Oncology Care, Scale A.I. and Patient-focused Technologies Business Wire DENVER- VieCure , Inc. today announced the closing of its $25 million Series A growth equity investment, led by Northpond Ventures . An undisclosed investor is also contributing to the round. VieCure, an oncology clinical informatics company with an artificial intelligence (AI) enabled clinical decision support platform, will use the new funding to accelerate the deployment of its next generation clinical decision support solution, and grow the sales and business development organization ...
4/20/2021 VieCure Announces $25 Million Series A Investment Led by Northpond Ventures to Improve Oncology Care, Scale A.I. and Patient-focused Technologies Business Wire Valdosta City Schools reports eight new student COVID cases AP VieCure Announces $25 Million Series A Investment Led by Northpond Ventures to Improve Oncology Care, Scale A.I. and Patient-focused Technologies Apr 20, 2021 1 hr agoDENVER--(BUSINESS WIRE)--Apr 20, 2021--VieCure , Inc. today announced the closing of its $25 million Series A growth equity investment, led by Northpond Ventures . An undisclosed investor is also contributing to the ...
4/20/2021 VieCure Announces $25 Million Series A Investment Led by Northpond Ventures to Improve Oncology Care, Scale A.I. and Patient-focused Technologies tmcnet.com FREE eNEWSLETTERS TMCnet News VieCure Announces $25 Million Series A Investment Led by Northpond Ventures to Improve Oncology Care, Scale A.I. and Patient-focused Technologies [April 20, 2021] VieCure Announces $25 Million Series A Investment Led by Northpond Ventures to Improve Oncology Care, Scale A.I. and Patient-focused TechnologiesVieCure , Inc. today announced the closing of its $25 million Series A growth equity investment, led by Northpond Ventures . An undisclosed ...
4/20/2021 VieCure Announces $25 Million Series A Investment Led by Northpond Ventures to Improve Oncology Care, Scale A.I. and Patient-focused Technologies vcaonline.com Venture Capital Database 2021 Now Available! VieCure Announces $25 Million Series A Investment Led by Northpond Ventures to Improve Oncology Care, Scale A.I. and Patient-focused Technologies Financing to support accelerated deployment of the VieCure platform in cancer centers nationwide and globally, along with expanded partnerships with life sciences, molecular labs, payors, and oncology drug distribution companies DENVER, April 20, 2021-- VieCure, Inc. today announced the closing of its $25 ...
4/20/2021 VieCure Announces $25 Million Series A Investment Led by Northpond Ventures to Improve Oncology Care, Scale A.I. and Patient-focused Technologies financialbuzz.com VieCure , Inc. today announced the closing of its $25 million Series A growth equity investment, led by Northpond Ventures . An undisclosed investor is also contributing to the round. VieCure, an oncology clinical informatics company with an artificial intelligence (AI) enabled clinical decision support platform, will use the new funding to accelerate the deployment of its next generation clinical decision support solution, and grow the sales and business development organization in ...
4/7/2021 Vizgen Secures $37M Series B Financing to Advance Spatial Genomics Through Commercialization of MERSCOPE‚Ñ¢ Platform Yahoo News ... science company dedicated to advancing human health by visualizing single-cell spatial genomics information, has closed a $37 million Series B financing. The financing was co-led by Novalis LifeSciences LLC , and current investor Northpond Ventures . Also participating in the round were new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund. Current investors joining the round included ARCH Venture Partners and David Walt, Ph.D ...
4/7/2021 Vizgen Secures $37M Series B Financing to Advance Spatial Genomics Through Commercialization of MERSCOPE‚Ñ¢ Platform | Business Wire Business Wire CAMBRIDGE, Mass.- Vizgen , the life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, has closed a $37 million Series B financing. The financing was co-led by Novalis LifeSciences LLC , and current investor Northpond Ventures . Also participating in the round were new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund. Current investors joining the round included ARCH Venture ...
4/7/2021 Vizgen Raises $37M in Series B Financing genomeweb.com staff reporterNEW YORK – Spatial genomics startup Vizgen said on Thursday that it has raised $37 million in an oversubscribed Series B financing.Novalis LifeSciences and Northpond Ventures led the round, joined by new investors Tao Capital Partners, Pura Vida Investments, and an unspecified US endowment fund as well as existing investors Arch Venture Partners and David Walt. Walt, a professor at Harvard Medical School, is a Vizgen cofounder ...
4/7/2021 Vizgen Secures $37M Series B Financing to Advance Spatial Genomics Through Commercialization of MERSCOPE‚Ñ¢ Platform vcaonline.com ... science company dedicated to advancing human health by visualizing single-cell spatial genomics information, has closed a $37 million Series B financing. The financing was co-led by Novalis LifeSciences LLC, and current investor Northpond Ventures . Also participating in the round were new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund. Current investors joining the round included ARCH Venture Partners and David Walt, Ph.D ...
4/7/2021 Vizgen Secures $37M Series B Financing to Advance Spatial Genomics Through Commercialization of MERSCOPE Platform financialbuzz.com Vizgen , the life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, has closed a $37 million Series B financing. The financing was co-led by Novalis LifeSciences LLC , and current investor Northpond Ventures . Also participating in the round were new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund. Current investors joining the round included ARCH Venture Partners and ...
3/24/2021 Scipher Medicine Announces $82 Million Financing biomedreports.com aMoon and Northpond Ventures led the round. -Additional investors include Echo Health Ventures, Khosla Ventures and Alumni Ventures. -Financing will support commercialization of precision medicine Prism TM portfolio of blood tests and data partnerships in autoimmune diseases with payers, providers and pharma.WALTHAM, Mass., March 24, 2021 (GLOBE NEWSWIRE) -aMoon and Northpond Ventures led the round. -Additional investors include Echo Health Ventures, Khosla Ventures and Alumni Ventures. -Financing will support ...
3/24/2021 Scipher Medicine Announces $82 Million Financing vcaonline.com Scipher Medicine Announces $82 Million Financing -aMoon and Northpond Ventures led the round. -Additional investors include Echo Health Ventures, Khosla Ventures and Alumni Ventures. -Financing will support commercialization of precision medicine PrismTM portfolio of blood tests and data partnerships in autoimmune diseases with payers, providers and pharma. WALTHAM, Mass., March 24, 2021-- Scipher Medicine≈Ω, a precision immunology company matching patients with the most effective therapy, announced the completion of ...